For CML, there were 2.4 oncogene mutations, 0.3 driver gene mutations, and 1.69 tumor suppressor mutations per sample, with 53% of sample containing a RUNX1 mutation and 38% a TP53 mutation [37] (Additional file 3: Table S2). This evidence concerns the gene RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive.